Home » U.S. FDA, EMA Collaborate to Harmonize Biosimilars Pathways
U.S. FDA, EMA Collaborate to Harmonize Biosimilars Pathways
July 11, 2011
CHICAGO— The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have set up a new cluster on biosimilar medicines, and that could help the FDA catch up in its development of an abbreviated pathway to approve the generic biologics.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor